PresentationLadies and gentlemen, thank you for joining us, and welcome to Belite Bio's Phase III DRAGON Topline Results Conference Call. [Operator Instructions] I will now hand the conference over to Nathan Mata. Please go ahead.Nathan L. MataChief Scientific Officer Welcome, everyone, to the webcast presentation of topline data from our 2-year Phase III trial of Tinlarebant in Stargardt disease. This pivotal trial is known as the DRAGON study and is the largest interventional trial ever conducted in adole ...